Project Grant R56CA280636
Award Date
9/18/24
Completion Date
8/31/26
Dollars Obligated
$483K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $163,500.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The University of Texas MD Anderson Cancer Center to unravel the mechanisms of diffuse-type gastric cancer (DGAC) tumorigenesis and lay a foundation for DGAC therapy development. The researchers have established a model system using genetically engineered gastric organoids and single-cell transcriptomics to delineate the cell dynamics, cells of origin, and...
The National Cancer Institute (NCI) awarded a $872,878 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of California, Davis (UC Davis) to conduct the Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR). The five-year project, which began on September 1, 2024, aims to study the genetic architecture of breast cancer risk in Hispanic/Latina populations and improve predictive models for risk stratification. The project leverages the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $125,783.00 to The University of Texas MD Anderson Cancer Center to conduct research on advanced gastric adenocarcinoma (GAC). The key objectives are to: 1) Determine the mechanisms of CDH1-inactivated advanced GAC progression, focusing on the roles of SOX4 and EZH2; and 2) Evaluate molecular subtype-based responses to immune checkpoint blockade. The research leverages murine organoid...
The University of California, Davis was awarded a $573,240 Project Grant by the National Institute on Minority Health and Health Disparities (CFDA Program 93.307, Minority Health and Health Disparities Research) on September 9, 2024. This grant, titled "Advancing Indigenous Cancer Health Equity Through a Community-Centered Framework", aims to address critical issues that have perpetuated cancer health disparities among American Indians and Alaska Natives (AIANs). The key products and...
The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
This federal Project Grant award of $1,126,905.00 from the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397) supports research on the role of immunosuppression in the tumor microenvironment in Hispanic/Latino patients with breast cancer. The award is held by the University of Southern California (USC) and will be conducted in Los Angeles, CA from August 1, 2024 to July 31, 2026. The funded research aims to advance understanding of cancer biology,...
The National Cancer Institute (NCI) awarded a $564,414 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant will fund a 5-year research project to: 1) Develop and validate a predictive model based on electronic health record data that can accurately identify individuals at high risk for gastric cancer, and 2) Develop a mathematical model to assess the potential...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $764,565 to the Sloan-Kettering Institute for Cancer Research to conduct a large prospective investigation to validate promising metabolite biomarkers for gastric cancer risk and discover novel biomarkers. The 5-year project will harmonize pre-diagnostic plasma samples and epidemiological data from ~1,200 gastric cancer cases and 1,600 matched controls across six...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biological mechanisms contributing to racial disparities in head and neck cancer outcomes, particularly among Black patients. The key objectives are to: 1) Develop a prognostic model using gene expression signatures to predict disease progression in early-stage oral squamous cell...
The University of California, San Diego (UCSD) was awarded a $444,952 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to conduct research exploring the impact of base deaminase deregulation on precancer evolution. The 5-year grant, which commenced on December 1, 2024, aims to elucidate the relative roles of APOBEC3C and ADAR1 deaminases in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research...